Journal
IMMUNITY
Volume 46, Issue 3, Pages 379-392Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2017.02.017
Keywords
-
Categories
Funding
- NIH [1U19AI109662, RO1-AI51321, AI091707, K01CA175127, DK095666, K08DK090576, R01HL131093]
- Greenberg Medical Research Institute
- Starr Foundation
- Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy [DE-AC02-05CH11231]
Ask authors/readers for more resources
Type III interferons (IFN-lambda s) signal through a heterodimeric receptor complex composed of the IFN-lambda R1 subunit, specific for IFN-lambda s, and interleukin-10Rb (IL-10Rb), which is shared by multiple cytokines in the IL-10 superfamily. Low affinity of IL-10Rb for cytokines has impeded efforts aimed at crystallizing cytokine-receptor complexes. Weused yeast surface display to engineer a higher-affinity IFN-lambda variant, H11, which enabled crystallization of the ternary complex. The structure revealed that IL-10Rb uses a network of tyrosine residues as hydrophobic anchor points to engage IL-10 family cytokines that present complementary hydrophobic binding patches, explaining its role as both a cross-reactive but cytokine-specific receptor. H11 elicited increased antiproliferative and antiviral activities in vitro and in vivo. In contrast, engineered higher-affinity type I IFNs did not increase antiviral potency over wild-type type I IFNs. Our findings provide insight into cytokine recognition by the IL-10R family and highlight the plasticity of type III interferon signaling and its therapeutic potential.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available